NOISETimeline
Coverage history

Assembled by NOISE.

Timeline / 3 linked reports

Moderna shares plunge on leaked cancer vaccine data despite positive results

This timeline contains reports linked by the NOISE desk. Automatic links follow a check of each report and its sources. It does not include all coverage of the subject.

Go to the latest report

  1. Report 1

    Moderna shares plunge on leaked cancer vaccine data despite positive results

    Moderna shares fell as much as 25% on Thursday after partial data on its experimental cancer vaccine with Merck leaked ahead of the full release. The complete results, published later that day, showed the vaccine plus Keytruda cut the risk of recurrence or death by 42% in certain melanoma patients versus Keytruda alone, and reduced the risk of distant spread or death by 38%. Analysts said the share decline reflected elevated investor expectations rather than disappointing efficacy. The vaccine is personalized and is also being studied in lung, bladder, and kidney cancers.

    From Evening NOISE.

  2. Report 2

    Moderna and Merck mRNA vaccine cuts melanoma death and recurrence by 42%

    Moderna and Merck announced their personalized mRNA cancer vaccine combined with Keytruda cut the risk of melanoma recurrence or death by 42% in a Phase 3 trial. Among 1,137 patients with surgically removed stage IIB-IV melanoma, 82% of those on the vaccine combination were alive without recurrence after two years, versus 70% receiving Keytruda alone. The results, scheduled for presentation at the European Society of Medical Oncology meeting in Madrid, are the first late-stage evidence of an mRNA vaccine improving outcomes over standard-of-care immunotherapy. The companies are discussing approval with regulators.

    From Morning NOISE.

  3. Report 3

    Personalized mRNA vaccine cuts melanoma recurrence risk by over 40%

    Merck and Moderna reported that their personalized mRNA vaccine reduced the risk of melanoma recurrence or death by 42 percent in a Phase 3 trial. Among 1,137 high-risk patients who had surgery to remove their tumors, those who received the vaccine alongside pembrolizumab had an 82.2 percent recurrence-free rate after about 25 months, versus 70 percent with pembrolizumab alone. The vaccine, tailored to each patient's tumor, is awaiting FDA approval.

    From Morning NOISE.